Abstract
The effectiveness of pharmacist interventions is supported by high-level evidence from around the world. Such effectiveness combined with high levels of patient satisfaction and support renders pharmacy interventions as a great option to reduce the strain on the overstretched healthcare systems. But before deciding to go down that path, we need to confirm that it is a cost-effective option.
This entry discusses the evidence of the economic evaluation of pharmacist prescribing in community pharmacy. The reviewed research clearly indicates that pharmacist prescribing in a community pharmacy setting was associated with cost savings when compared to interventions by other healthcare providers or usual care. Yet, despite this positive evidence, more primary literature is still needed to fill this knowledge gap, provide further evidence to support full scope of practice for community pharmacists, and present policy makers around the world with an innovative and cost-effective option to reduce the burden on the already overstrained healthcare system.
This is a preview of subscription content, log in via an institution to check access.
References
Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki RT. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open. 2013;3(9). https://doi.org/10.1136/bmjopen-2013-003154.
Al Hamarneh YN, Johnston K, Marra CA, Tsuyuki RT. Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study. Can Pharm J (Ott). 2019;152(4):257–66. Published 2019 Jun 10. https://doi.org/10.1177/1715163519851822.
Al Harmarneh YN, Lamb S, Donald M, et al. Pharmacist prescribing and care improves cardiovascular risk, but what do patients think? A substudy of the RxEACH study. Can Pharm J. 2018;151(4):223–7. https://doi.org/10.1177/1715163518779092.
American Pharmacists Association. Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model. Version 2.0. 2008. Available online from: https://s3.amazonaws.com/filehost.pharmacist.com/CDN/PDFS/Practice/core_elements_of_an_mtm_practice.pdf?AWSAccessKeyId=AKIAYICBVAN2V7IWVG4T&Expires=1623105746&Signature=WbQKNgEf0FKQlFyOaQXjSg22qes%3D. Accessed 7 June 2021.
Asthma – United States: 1980-90. MMWR Morb Mortal Wkly Rep. 1992;41:733–5.
Bajorek B, Lemay KS, Magin P, Roberts C, Armour CL. Implementation and evaluation of a pharmacist-led hypertension management service in primary care: outcomes and methodological challenges. Pharm Pract (Granada). 2016;14(2). https://doi.org/10.18549/PharmPract.2016.02.723.
Baqir W, Learoyd T, Sim A, Todd A. Cost analysis of a community pharmacy ‘minor ailment scheme’ across three primary care trusts in the North East of England. J Public Health (Oxf). 2011;33(4):551–5. https://doi.org/10.1093/pubmed/fdr012. Epub 2011 Feb 21. PMID: 21339201.
Bartsch SM, Taitel MS, DePasse JV, Cox SN, Smith-Ray RL, Wedlock P, Singh TG, Carr S, Siegmund SS, Lee BY. Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic. Vaccine. 2018;36(46):7054–63. https://doi.org/10.1016/j.vaccine.2018.09.040. Epub 2018 Oct 16. PMID: 30340884; PMCID: PMC6279616.
Beahm NP, Smyth DJ, Tsuyuki RT. Outcomes of Urinary Tract Infection Management by Pharmacists (RxOUTMAP): a study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community. Can Pharm J (Ott). 2018;151(5):305–14.
Boyd KA, Briggs AH. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction. 2009;104(2):317–25. https://doi.org/10.1111/j.1360-0443.2008.02449.x. PMID: 19149829.
Brown S, Al Hamarneh YN, Tsuyuki RT, Nehme K, Sauriol L. Economic analysis of insulin initiation by pharmacists in a Canadian setting: the RxING study. Can Pharm J (Ott). 2016;149(3):130–7. https://doi.org/10.1177/1715163516640813. Epub 2016 Apr 5. PMID: 27212963; PMCID: PMC4860749.
Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial. BMJ Open. 2013;3:e002361.
Csikar JI, Douglas GV, Pavitt S, Hulme C. The cost-effectiveness of smoking cessation services provided by general dental practice, general medical practice, pharmacy and NHS Stop Smoking Services in the North of England. Community Dent Oral Epidemiol. 2016;44(2):119–27. https://doi.org/10.1111/cdoe.12195. Epub 2015 Sep 24. PMID: 26403940.
Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37–46.
Deprescribing research team. Reducing medications safely to meet life’s changes. 2021. Available online from: https://deprescribing.org/. Accessed 8 June 2021.
Derbyshire Local Pharmaceutical Committee. Flu-Fighting – a Growing Role for Pharmacy. 2015. Available online from: https://www.derbyshirelpc.org/latest-news/lpc-chairmans-blog/. Accessed 31 May 2021.
Evans RE, Mullally DI, Wilson RW, et al. National trends in the mortality and morbidity of asthma in the US. Chest. 1987;91(Suppl):L65S–74S.
Grenier J, Leiter LA, Langer A, Goldin L, Teoh H, Connelly KA, Cheng AYY, Tan MK, Fitchett D, McGuire DK, Goodman SG, Yan AT. Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. Eur Heart J. 2016;2(4):277–84. https://doi.org/10.1093/ehjqcco/qcw013.
Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J Oncol Pharm Pract. 2020;26(1):13–22. https://doi.org/10.1177/1078155219833441.
Kim JJ, Tian AH, Pham L, Nakhla N, Houle SKD, Wong WWL, Alsabbagh MW. Economic evaluation of pharmacists prescribing for minor ailments in Ontario, Canada: a cost-minimization analysis. Int J Pharm Pract. 2021;29(3):228–34. https://doi.org/10.1093/ijpp/riab006. PMID: 33778880; PMCID: PMC8152214.
Klepser DG, Bisanz SE, Klepser ME. Cost-effectiveness of pharmacist provided treatment of adult pharyngitis. Am J Manag Care. 2012;18(4):e145–54.
Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott). 2017;150(3):184–97. https://doi.org/10.1177/1715163517701109. PMID: 28507654; PMCID: PMC5415065.
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018;320(18):1889–98. https://doi.org/10.1001/jama.2018.16131.
McLean W, Gillis J, Waller R. The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J. 2003;10(4):195–202. https://doi.org/10.1155/2003/736042. PMID: 12851665.
Neilson AR, Bruhn H, Bond CM, et al. Pharmacist-led management of chronic pain in primary care: costs and benefits in a pilot randomised controlled trial. BMJ Open. 2015;5(4):e006874. https://doi.org/10.1136/bmjopen-2014-006874.
O’Reilly DJ, Blackhouse G, Burns S, et al. Economic analysis of pharmacist-administered influenza vaccines in Ontario, Canada. Clinicoecon Outcomes Res. 2018;10:655–63. Published 2018 Oct 24. https://doi.org/10.2147/CEOR.S167500.
Okada H, Johnston K, Nakayama T, Marra C, Tsuyuki RT. Economic evaluation of pharmacists tackling the burden of hypertension in Japan. Hypertension. 2019;74(6):e54–5. https://doi.org/10.1161/HYPERTENSIONAHA.119.13527. Epub 2019 Oct 14. PMID: 31607176.
Rafferty E, Yaghoubi M, Taylor J, Farag M. Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan. Cost Eff Resour Alloc. 2017;11(15):3. https://doi.org/10.1186/s12962-017-0066-7. PMID: 28400708; PMCID: PMC5387257.
Rodriguez MI, Hersh A, Anderson LB, Hartung DM, Edelman AB. Association of pharmacist prescription of hormonal contraception with unintended pregnancies and medicaid costs. Obstet Gynecol. 2019;133(6):1238–46. https://doi.org/10.1097/AOG.0000000000003265. Erratum in: Obstet Gynecol. 2019;134(1):182. PMID: 31135740.
Rupp MT. Value of community pharmacists’ interventions to correct prescribing errors. Ann Pharmacother. 1992;26(12):1580–4. https://doi.org/10.1177/106002809202601218. PMID: 1482816
Sanyal C, Husereau DR, Beahm NP, Smyth D, Tsuyuki RT. Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists. BMC Health Serv Res. 2019;19(1):499. https://doi.org/10.1186/s12913-019-4303-y. PMID: 31319844; PMCID: PMC6639967.
Sanyal C, Turner JP, Martin P, Tannenbaum C. Cost-effectiveness of pharmacist-led deprescribing of NSAIDs in community-dwelling older adults. J Am Geriatr Soc. 2020;68(5):1090–7. https://doi.org/10.1111/jgs.16388. Epub 2020 Feb 27. PMID: 32105355.
Shiu JR, Simpson SH, Johnson JA, Tsuyuki RT. Quantifying opportunities to affect diabetes management in the community. Can Pharm J. 2006;139:37–8.
Soon JA, Meckley LM, Levine M, Fielding D, Ensom MHH, Marciante KD. PIHI19 Cost-effectiveness of pharmacist prescribing authority for emergency contraception in British Columbia. Value Health. 2005;8(3):303.
Tam-Tham H, Clement F, Hemmelgarn BR, Manns BJ, Klarenbach SW, Tonelli M, Tsuyuki RT, Al Hamarneh YN, Penko J, Weaver CGW, Au F, Weaver RG, Jones CA, McBrien KA. A cost analysis and cost-utility analysis of a community pharmacist-led intervention on reducing cardiovascular risk: the Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH). Value Health. 2019;22(10):1128–36. https://doi.org/10.1016/j.jval.2019.05.012. Epub 2019 Aug 17. PMID: 31563255.
Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control. 2008;17(3):177–82. https://doi.org/10.1136/tc.2007.022368. Epub 2008 Feb 19. PMID: 18285385.
Tsuyuki RT, Al Hamarneh YN. Chapter 5: Community Pharmacy in Canada. In: Community Pharmacy: an international comparison. Nova Science Publishers, New York; 2016. ISBN: 978-1-53610-213-0.
Tsuyuki RT, Houle SKD, Charrois TL, et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community. Circulation. 2015;132(2):93–100. https://doi.org/10.1161/CIRCULATIONAHA.115.015464.
Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR. The effectiveness of pharmacist interventions on cardiovascular risk: the Multicenter Randomized Controlled RxEACH Trial. J Am Coll Cardiol. 2016a;67(24):2846–54. https://doi.org/10.1016/j.jacc.2016.03.528.
Tsuyuki RT, Rosenthal M, Pearson GJ. A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J. 2016b;149(5):283–92. https://doi.org/10.1177/1715163516662291.
Turner JP, Sanyal C, Martin P, Tannenbaum C. Economic evaluation of sedative deprescribing in older adults by community pharmacists. J Gerontol A Biol Sci Med Sci. 2021;76(6):1061–7. https://doi.org/10.1093/gerona/glaa180. PMID: 32761069.
van der Laan DM, Langendoen-Gort M, Nijpels G, Boons CCLM, Elders PJM, Hugtenburg JG. Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies. Int J Clin Pharm. 2019;41(4):1031–46. https://doi.org/10.1007/s11096-019-00845-z.
Weatherall B, Greenwood B, Chee HL, Wasi P. Ch 5: Science and technology for disease control: past, present, and future. In: Disease control priorities in developing countries, 2nd ed. Oxford University Press, New York; 2006.
Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med. 2005;20:1091–6.
Author information
Authors and Affiliations
Corresponding author
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Al Hamarneh, Y.N. (2023). Economic Evidence for Pharmacist Prescribing in Community Pharmacy. In: Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-50247-8_69-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-50247-8_69-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-50247-8
Online ISBN: 978-3-030-50247-8
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences